**Pseudomonas aeruginosa** infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment*

Luiz Vicente Ribeiro Ferreira da Silva Filho, Flavia de Aguiar Ferreira, Francisco José Caldeira Reis, Murilo Carlos Amorim de Britto, Carlos Emilio Levy, Otavio Clark, José Dirceu Ribeiro

**Abstract**

Evidence-based techniques have been increasingly used in the creation of clinical guidelines and the development of recommendations for medical practice. The use of levels of evidence allows the reader to identify the quality of scientific information that supports the recommendations made by experts. The objective of this review was to address current concepts related to the clinical impact, diagnosis, and treatment of **Pseudomonas aeruginosa** infections in patients with cystic fibrosis. For the preparation of this review, the authors defined a group of questions that would be answered in accordance with the principles of PICO—an acronym based on questions regarding the Patients of interest, Intervention being studied, Comparison of the intervention, and Outcome of interest. For each question, a structured review of the literature was performed using the Medline database in order to identify the studies with the methodological design most appropriate to answering the question. The questions were designed so that each of the authors could write a response. A first draft was prepared and discussed by the group. Recommendations were then made on the basis of the level of scientific evidence, in accordance with the classification system devised by the Oxford Centre for Evidence-Based Medicine, as well as the level of agreement among the members of the group.

**Keywords:** Cystic fibrosis/diagnosis; Cystic fibrosis/drug therapy; Pseudomonas aeruginosa; Evidence-based medicine.

**Resumo**

As técnicas de medicina baseada em evidências são cada vez mais utilizadas para a construção de diretrizes clínicas e recomendações para a prática médica. O uso de níveis de evidências permite que o leitor identifique a qualidade da informação científica que sustenta as recomendações feitas pelos especialistas. Esta revisão teve por objetivo abordar conceitos atuais sobre o impacto clínico, diagnóstico e tratamento das infecções por **Pseudomonas aeruginosa** em pacientes com fibrose cística. Para a elaboração desta revisão, o grupo de autores definiu as perguntas que seriam respondidas, seguindo os preceitos de PICO, acrônimo baseado em perguntas referentes aos Pacientes de interesse, Intervenção a ser estudada, Comparação da intervenção e Outcome (desfecho) de interesse. Para cada pergunta, uma revisão estruturada da literatura foi realizada nas bases de dados do Medline, buscando identificar os estudos com desenho metodológico mais adequado para responder à questão. As perguntas foram designadas para que cada um dos autores redigisse uma resposta, e um primeiro rascunho foi elaborado e discutido pelo grupo em uma reunião presencial. Após essa discussão, recomendações foram emitidas com base na força das evidências e na concordância entre os membros do grupo segundo o sistema de classificação do Oxford Centre for Evidence Based Medicine.

**Descritores:** Fibrose cística/diagnóstico; Fibrose cística/quimioterapia; Pseudomonas aeruginosa; Medicina baseada em evidências.

*Study carried out at the Instituto da Criança, University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil. Correspondence to: Luiz Vicente Ribeiro Ferreira da Silva Filho. Rua Gregório Paes de Almeida, 1231, Vila Madalena, CEP 05450-001, São Paulo, SP, Brasil. Tel. 55 11 5543-9677. Email: vicres@usp.br Financial support: This study received financial support from Novartis Brazil. Submitted: 11 February 2013. Accepted, after review: 17 April 2013.
Introduction

Cystic fibrosis (CF) is a complex genetic disease with multisystem involvement and pulmonary manifestations of a suppurative nature. Patients with CF are born with structurally normal lungs, but develop a progressive respiratory disease with recurrent chronic infections that result in the formation of bronchiectasis and lead to respiratory failure, which is the leading cause of death in these subjects.

The basic defect in CF is related to chlorine transport through epithelial cell membranes by the cystic fibrosis transmembrane conductance regulator (CFTR) protein, the dysfunction of which was identified as being the principal mechanism of the disease in 1989. There are more than 1,500 described mutations in the CFTR gene sequence, but most of them have very low prevalence, the ΔF508 mutation (deletion of phenylalanine residue at position 508) being the most prevalent worldwide.

Patients with CF are peculiarly susceptible to infection and colonization of the respiratory tract with pathogens, such as Staphylococcus aureus, Haemophilus influenzae, and glucose-nonfermenting gram-negative bacilli, including Pseudomonas aeruginosa, Burkholderia cepacia complex, and Stenotrophomonas maltophilia, among others.

The prevalence of these pathogens varies with age, with S. aureus infections usually occurring early (generally in the first months of life) and pathogens such as P. aeruginosa tending to appear a little later, although this sequence of infections is greatly influenced by therapeutic and microbiological surveillance practices, as well as by hospitalizations, exposure to other patients with CF, and environmental conditions that have yet to be defined.

The etiologic diagnosis of respiratory infections in patients with CF is habitually established through culture of respiratory tract samples, such as sputum and oropharyngeal swabs, the latter method generally being used in infants and children who are unable to expectorate sputum.

In recent years, some attention has been given to alternative methods of diagnosis, such as serology and molecular techniques, especially for early identification of infection with P. aeruginosa, a pathogen that has the greatest impact on this group of patients.

P. aeruginosa infections typically evolve to a pattern of persistence (chronicity), and strains undergo a phenotypic change, which is characterized by the production of a polysaccharide known as alginate. This bacterial phenotype, known as the mucoid phenotype, is associated with the greater difficulty in eradicating the pathogen, eliciting a major inflammatory response and resulting in accelerated functional loss and poorer prognosis.

Since the early 1990s, various treatment centers for patients with CF have recommended eradication therapies for initial P. aeruginosa infection, which is when strains are more susceptible to antimicrobials, in order to prevent the chronicity of the infection. In addition, strategies to suppress P. aeruginosa (or to reduce the bacterial load) with the use of inhaled antibiotics are one of the major therapeutic resources in the management of patients chronically infected with P. aeruginosa, causing improvement in pulmonary function, reducing the frequency of respiratory exacerbations, and improving the quality of life of these patients.

Despite the growing knowledge in the field of respiratory infections in patients with CF, there are still many questions regarding the knowledge of the actual clinical impact, the most appropriate diagnostic methods, and the evidence on the treatment of P. aeruginosa infections. Evidence-based techniques have been increasingly used in the creation of clinical guidelines and the development of recommendations for medical practice. This type of approach allows the systematic use of available scientific information, with less emphasis on isolated experiences. The objective of the present review was to address current concepts related to the clinical impact, diagnosis, and treatment of P. aeruginosa infections in patients with CF.

Methods

For the preparation of this study, the following steps were performed:

1. Question preparation: the authors, in a preliminary meeting, defined a group of questions that would be answered in accordance with the principles of PICO—an acronym based on questions regarding the Patients of interest, Intervention being studied, Comparison of the intervention, and Outcome of interest. The questions were designed so that one of the authors could write a response.

2. Search of the literature: an initial search of the literature was conducted using
the Medline database and search terms related to each question. One of the authors, who is an expert in evidence-based medicine, made the initial selection of relevant studies, which were sent to each responsible author for preparing the responses. These authors then conducted their own search and added other references that were judged relevant.

3. First draft of responses: each author was responsible for writing responses that were subsequently discussed by the entire group at a face-to-face meeting.

4. Discussion meeting: the group had a face-to-face meeting to discuss and, if necessary, to make changes to the responses proposed by each author separately. In that meeting, new information was sought and added to the original text. In addition, there was an explicit discussion about the level of evidence (LE) of the information, in accordance with the criteria set out by the Oxford Centre for Evidence-Based Medicine in 2011, which are shown in Chart 1.

5. Final draft: at the end of the meeting, each author sent the consensus response to the expert in evidence-based medicine, who was responsible for reviewing the LE, revising the text, and checking the references.

6. Revision: each author revised and approved the final draft of their responses and of the manuscript.

**Questions addressed in the study**

1. Does early *P. aeruginosa* colonization worsen the prognosis of patients with CF?

2. Can serologic testing for anti-*Pseudomonas* antibodies be useful for early detection of infection with this agent?

3. Does eradication of initial colonization with *P. aeruginosa* improve the prognosis in CF?

4. How does one identify and treat acute pulmonary exacerbations (APEs) in patients colonized with *P. aeruginosa*?

**Chart 1 - Grades of recommendation and levels of evidence of scientific articles.**

| Grade of recommendation | Strength of evidence |
|--------------------------|----------------------|
| A: More consistent experimental or observational studies | Studies on prognosis |
| B: Less consistent experimental or observational studies | |
| C: Case reports (uncontrolled studies) | |
| D: Opinion without critical appraisal, based on consensus, physiological studies, or animal models | |

| Level of evidence | Studies on prognosis | Studies on treatment |
|-------------------|----------------------|----------------------|
| 1a | Systematic review of cohort studies (inception cohort), validated in different populations | Systematic review of two or more independent randomized studies rated as level 1b |
| 1b | Individual cohort studies (inception cohort) | Randomized study of good methodological quality, including a sufficient number of patients |
| 2a | Systematic review of either retrospective cohort studies or untreated control groups in randomized studies | Systematic review of level 2b cohort studies |
| 2b | Retrospective cohort studies or follow-up of untreated control groups in randomized studies | Individual cohort studies (including poor quality randomized studies) |
| 3a | Systematic review of level 3b case-control studies | |
| 3b | Case series | |
| 4 | Case series | |
| 5 | Expert opinions | Expert opinions without explicit critical appraisal, or based on pathophysiology |

*In accordance with the Oxford Centre for Evidence-Based Medicine.*

J Bras Pneumol. 2013;39(4):495-512
5. When should chronic inhaled antibiotic therapy be initiated in CF? Which inhaled antibiotics can be used in the treatment of chronic *P. aeruginosa* infection in CF?

6. Does adherence to clinical treatment affect the prognosis of patients with CF?

7. Is azithromycin efficacious in slowing the progression of lung disease in CF patients colonized with *P. aeruginosa*?

8. Is there a good correlation between antibiogram results and clinical response in chronic *P. aeruginosa* infection?

9. Does multidrug-resistant *P. aeruginosa* infection worsen prognosis?

**Does early *P. aeruginosa* colonization worsen the prognosis of patients with CF?**

**Definitions**

Colonization means the presence of bacteria as detected by colony culture, i.e., by isolation of the bacterium in culture. Colonization can be initial (or acute)—in the first bacterial isolations—or chronic, in accordance with the referral center criteria: three or more positive cultures for *P. aeruginosa* within a 6-month period, with an interval of at least one month between them or more than 50% of positive cultures within 12 months.\(^{(14)}\)

Various parameters are used to characterize the prognosis in CF. The most common are pulmonary function testing and median survival: pulmonary function is in turn the best predictor of survival \((LE \ 2b)\).\(^{(15)}\)

Initial colonization with *P. aeruginosa* in children under 2 years of age significantly increases morbidity, and its association with *S. aureus* from the beginning significantly increases the mortality rate in the first 10 years after diagnosis \((LE \ 2b)\).\(^{(10,16)}\) The radiographic score deteriorates significantly and the Tiffeneau index \((FEV_1/FVC \ ratio)\) falls more rapidly after *P. aeruginosa* acquisition in patients diagnosed by newborn screening \((LE \ 2b)\).\(^{(17)}\) Data from the U.S. Cystic Fibrosis Foundation national registry showed that, between 1990 and 1998, the presence of *P. aeruginosa* was the greatest predictor of morbidity and mortality in patients aged 1-5 years \((n = 3,325)\)—with the risk of death being 2.6 times higher in those with than in those without *P. aeruginosa* respiratory infection \((LE \ 2b)\).\(^{(18)}\)

In a cohort study conducted in the USA, nonmucoid *P. aeruginosa* acquisition occurred in patients with a median age of 1 year, being observed in 29% of the patients under 6 months of age; identification of *P. aeruginosa* strains with a mucoid phenotype occurred in patients aged 4-16 years (median of 13 years). Eradication of nonmucoid *P. aeruginosa*, preventing chronicity and conversion to a mucoid phenotype, would allow a better prognosis \((LE \ 2b)\).\(^{(7)}\)

Early *P. aeruginosa* colonization predisposes to chronic colonization with this pathogen. A low level of chronic colonization can be achieved with intermittent use of inhaled antibiotics and less use of intravenous antibiotics. A lower level of chronic *P. aeruginosa* colonization improves prognosis \((LE \ 2b)\).\(^{(19)}\)

**Recommendation**

Early *P. aeruginosa* colonization, especially if associated with initial *S. aureus* colonization, worsens prognosis for morbidity and mortality \((LE \ 2b; \ grade \ of \ recommendation \ [GR] \ B)\).

**Can serologic testing for anti-*Pseudomonas* antibodies be useful for early detection of infection with this agent?**

Early identification of *P. aeruginosa* infection is essential for the initiation of eradication therapy, the goal of which is to prevent or delay chronic infection with the bacterium.\(^{(20)}\)

Respiratory infection with *P. aeruginosa* is routinely diagnosed by examination of sputum, oropharyngeal secretion, or laryngeal aspirates after respiratory therapy or inhalation of hypertonic sodium chloride solution \((3-7\%)\). Positive oropharyngeal secretion cultures have a high predictive value, although false-negative results can occur.\(^{(21)}\) Other resources used for diagnosis are bronchoalveolar lavage (BAL) culture, serology for detection of specific antibodies in serum, and methods for the detection of bacterial DNA (by PCR) in respiratory secretion specimens.\(^{(9)}\)

The difficulty in obtaining representative respiratory specimens from the airways of infants and children under 6 years of age indicates the need for the use of methods that can complement or be an alternative to culture.\(^{(22)}\) In the 1970s,
the initial experience of a group of researchers in Denmark,[23] regarding the use of serum precipitins to characterize stages of pulmonary infection with *P. aeruginosa* was the main incentive for the use of serological resources in early identification of infections with the pathogen.[24]

West et al.[25] evaluated a cohort of 68 infants diagnosed by neonatal screening and described the natural history of *P. aeruginosa* infections over a 15-year period. The detection of anti-*P. aeruginosa* antibodies allowed the identification of infection with the pathogen before it was isolated from a culture, with bacterial anti-cell lysate antibodies being detected 12 months before culture. Significant *P. aeruginosa* anti-cell lysate antibody titers were detected before or simultaneously with the first isolation of the bacterium in approximately 60% of the patients (LE 2b).[25]

In 2006, two studies reporting conflicting serological results were published in the same journal. Kappler et al.[26] used commercial ELISA kits in a prospective study involving 183 patients with CF and reported a sensitivity of 86%, a specificity of 96%, and a positive predictive value of 97%. Those authors propose *P. aeruginosa* eradication therapy in the event of a rise in antibody titers, even in the absence of positive cultures (LE 2b).[26] Tramper-Stranders et al.[27] used other ELISA kits in 220 CF patients with different *P. aeruginosa* infection status and found a sensitivity of 96% and a specificity of 79% for the combination of methods. The fact that 15 serological conversions were identified during the study period, with varying response patterns, draw attention to the possibility of failure in identifying early *P. aeruginosa* infection through the use of serological methods (LE 2b).[27]

Subsequently, Ratjen et al.[28] evaluating the usefulness of serological methods in initial *P. aeruginosa* infection in approximately 1,800 serum samples from 375 patients with CF, found inter-individual variability in antibody titers, but reported an association between the serological response and the intensity of the respiratory infection, which, according to the authors, suggested potential for the use of serological methods in conjunction with microbiology (LE 2b).[28]

In 2007 in Brazil, da Silva Filho et al.[29] in a study comparing single-sample PCR, culture, and serology in 87 patients with CF, reported that the combination of the three methods resulted in higher positivity, PCR being the method with the highest positivity. Because the study was cross-sectional, no further conclusions could be drawn (LE 3).[22] Methods for molecular identification of *P. aeruginosa* should be viewed with caution, because they do not depend on bacterial viability and they are affected by various technical aspects, such as DNA extraction methods, primers used, sample concentration, etc.[9]

Another group of authors, seeking to establish whether it would be possible to use saliva as a tool for the detection of anti-*P. aeruginosa* antibodies in patients with CF and in normal individuals,[29] described significant titers in the oral fluids from 15 of the 17 patients with CF but in none from the healthy volunteers (LE 2b).

Pressler et al.[30] comparatively analyzed three different serological methods (exotoxin A ELISA, CF-IgG ELISA, and counterimmunoelectrophoresis) in 791 Scandinavian patients with CF and concluded that the performance of the tests was very similar. Another relevant finding was the association between the antibody titers observed and the duration and characteristic of the infection, which means that serology could be used in characterizing the chronicity of the infection (LE 2b).[10]

In another study conducted in Brazil, Milagres et al.[31] studied 51 patients with CF over a 2-year period, using two types of antigen (bacterial lysate and recombinant PcrV). For 44% of the patients with previously negative cultures or intermittent isolations, serology allowed the detection of *P. aeruginosa*, on average, 21 months before its detection by culture, suggesting that the method should be part of the routine follow-up of patients with CF (LE 2b).[31]

More recently, two studies have generated more controversy on the subject. Hayes et al.[32] in an approximately 6-year longitudinal study evaluating 69 children with CF diagnosed by newborn screening, reported that serology allowed the early identification of *P. aeruginosa* infection in those patients. In contrast, Douglas et al.[33] described paired BAL culture and serology results and found a low positive predictive value and a high negative predictive value using BALF culture as a reference. In view of these findings, there is questioning regarding the potential of serology for monitoring *P. aeruginosa* infection (LE 2b), although recently, the role of BALF culture as a decision-making tool in the treatment of
respiratory infection in patients with CF has also been questioned.\(^\text{[34]}\)

**Recommendation**

Positive serology results and culture-negative samples of respiratory secretion should alert health professionals to perform a more thorough search for a probable infection, by repeating the test or by using methods that are more sensitive and more specific. In contrast, increasing levels of antibodies are associated with a greater likelihood of persistent chronic infection with the bacterium. Their use in routine practice remains controversial (LE 2b; GR B).

**Does eradication of initial colonization with P. aeruginosa improve the prognosis in CF?**

*P. aeruginosa* is the most common pathogen in lung infections in patients with CF. The importance of its early detection is due to its correlation with a more pronounced reduction in pulmonary function, which results in impaired quality of life and poorer prognosis of patients chronically colonized with the bacterium. Early identification of *P. aeruginosa* infection is essential for the initiation of eradication therapy, the goal of which is to prevent or delay chronic infection with the bacterium at a phase in which strains are more susceptible to antibiotics.

Studies dating back to the 1980s investigated the effects of early treatment in patients infected with *P. aeruginosa*, suggesting that early eradication could lead to a decrease in the number of patients with chronic colonization. Since the initial studies by Littlewood et al.,\(^\text{[35]}\) there has been growing evidence that the early initiation of antibiotic therapy is an effective strategy to delay chronic *P. aeruginosa* infection.\(^\text{[36-38]}\)

A broader assessment of the effects of eradication therapy was performed by Taccetti et al.,\(^\text{[12]}\) who, in a study of 47 patients, showed that the early use of oral ciprofloxacin + inhaled colomycin resulted in reduced chronicity, causing no increase in bacterial resistance or in the emergence of other pathogens. In addition, those authors found a reduction in pulmonary function decline and in treatment costs.\(^\text{[12]}\)

In a recently published study,\(^\text{[39]}\) the authors concluded that the implementation of an early intervention protocol led to decreased prevalence of chronic *P. aeruginosa* infection, improved pulmonary function, and decreased hospital costs (LE 1b). The decision on the best antimicrobial strategy for *P. aeruginosa* eradication remains controversial. In an open-label randomized multicenter study,\(^\text{[40]}\) patients with CF (age ≥ 6 months) and primary infection with *P. aeruginosa* were treated for 28 days or 56 days with inhaled tobramycin administered twice daily. The study showed that more than 90% of patients had negative cultures for *P. aeruginosa* one month after the end of treatment, and that most of those patients remained free from infection for up to 27 months. There was no significant difference when the period of treatment with inhaled tobramycin was extended to 56 days (LE 1b).\(^\text{[40]}\)

In another recent multicenter study,\(^\text{[41]}\) the participants were randomized 1:1 to one of four treatment algorithms for 18 months. The treatment regimens were as follows: (a) intermittent courses (every 3 months) of inhaled tobramycin (300 mg twice daily) for 28 days + oral ciprofloxacin (15–20 mg/kg twice daily) for 14 days; (b) intermittent courses (every 3 months) of inhaled tobramycin for 28 days + oral placebo for 14 days; (c) inhaled tobramycin for 28 days + oral ciprofloxacin for 14 days in the presence of a positive culture for *P. aeruginosa*; and (d) inhaled tobramycin for 28 days + oral placebo for 14 days in the presence of a positive culture for *P. aeruginosa*. Those authors concluded that, after 18 months, there were no differences in the rates of exacerbation or prevalence of *P. aeruginosa* between prophylactic treatment and treatment based on positive cultures. There was no additional benefit from the addition of ciprofloxacin during that study (LE 1b).\(^\text{[41]}\)

**Recommendation**

Evidence suggests that the early initiation of inhaled antibiotic therapy, combined or not with oral antibiotics, is an efficient strategy to delay chronic *P. aeruginosa* infection. Studies suggest that short-term eradication can be achieved (LE 1b; GR A).\(^\text{[42]}\)

**How does one identify and treat acute pulmonary exacerbations (APEs) in patients colonized with P. aeruginosa?**

In patients with CF, APEs are a common complication. Although there are published
guidelines for the management of APEs in patients with CF, it is not possible to know for sure which are the best treatment strategies, given the insufficient data.\(^2\)

Chronic *P. aeruginosa* infection becomes more common as patients grow older and is associated with increased morbidity and mortality. Chronic infection is interspersed with APEs, which require additional and more aggressive antibiotic therapy. There is evidence that APEs result in functional loss that often is not completely reversed by treatment.\(^43\)

In APEs with no obvious precipitating factor, several questions arise:

a. How does one define an APE?
b. Should intravenous therapy for an APE be administered in the home or in the hospital?
c. Which antibiotic(s) should intravenous therapy for an APE include?
d. Can (or should) aminoglycosides be used once daily?
e. What should be the duration of intravenous therapy for an APE?

**How does one define an APE?**

In 1994, Fuchs et al.\(^44\) established criteria for defining APEs in CF, criteria that were subsequently used in a number of scientific studies in the field. According to those authors, an APE could be defined as the clinical need for intravenous antibiotics as indicated by the presence of at least 4 of the 12 signs or symptoms described below:

- Change in sputum volume or color
- Hemoptysis
- Increased cough
- Increased dyspnea
- Increased malaise, fatigue, or lethargy
- Temperature over 38°C
- Anorexia or weight loss
- Maxillary sinus pain or sensitivity
- Change or increase in postnasal discharge
- Change in chest physical examination findings
- Decrease in FEV\(_1\), of 10% or higher
- New radiographic changes

Given that APEs have a negative impact on survival, quality of life, and costs (because of the high costs of hospitalizations and medications), they are an important outcome measure in clinical trials, and although various authors have proposed alternative methods for their objective characterization in patients with CF,\(^45-47\) this definition remains a source of controversy.\(^48\)

In 2011, a group of European experts met in Hamburg and proposed new consensus criteria for characterizing an APE\(^49\): the need for antibiotic therapy resulting from a recent change in at least 2 of the following 7 items:

- Change in sputum volume or color
- Increased cough
- Increased malaise, fatigue, or lethargy
- Anorexia or weight loss
- Decrease in FEV\(_1\), of 10% or higher
- New radiographic changes
- Increased dyspnea

Recommendation

There is insufficient evidence to recommend or refute intravenous home therapy for APEs,
and decisions should be made on a case-by-case basis (LE 5; GR D).

**Which antibiotic(s) should intravenous therapy for an APE include?**

Traditionally, intravenous administration of beta-lactam antibiotics combined with aminoglycosides has been the most commonly used therapeutic regimen in the treatment of APEs in patients with CF. Given that *P. aeruginosa* is a pathogen that develops resistance to antimicrobial agents relatively easily, the combination of drugs with different mechanisms of action can contribute to minimizing this risk. In a study conducted in England, the researchers reported a high prevalence of ceftazidime-resistant *P. aeruginosa* strains, possibly due to the practice of monotherapy with this drug in the institution (LE 4).

A systematic review published in 2005 included 27 studies comparing monotherapy with combination antibiotic therapy in the treatment of APEs in patients with CF. The studies were mostly of questionable methodological quality and were quite heterogeneous, complicating the analysis and interpretation of results. In contrast, some randomized studies have shown that combination antibiotic therapy is effective in the treatment of APEs in patients with CF (NE 2a). American guidelines recognize the deficiency in information but recommend that combination drug therapy be instituted.

**Recommendation**

There is evidence to recommend the combination of an aminoglycoside and a beta-lactam antibiotic for the treatment of APEs in patients with CF (LE 2a; GR B).

**Can (or should) aminoglycosides be used once daily?**

Aminoglycosides were originally studied and approved for use as a three-times-daily injection regimen. The recognition that the maximum bactericidal effect of aminoglycosides results from the serum peak values achieved motivated researchers in the late 1980s to evaluate once-daily aminoglycoside administration, and this strategy was found to be effective and safe in various clinical settings. In patients with CF, the results of a meta-analysis and of a systematic review indicate that once-daily aminoglycoside administration is effective and safer (LE 1a).

**Recommendation**

Aminoglycosides should be administered in a single daily dose in order to reduce side effects (LE 1a; GR A).

**What should be the duration of intravenous therapy for an APE?**

There are no clear guidelines on the optimal duration of intravenous antibiotic therapy in APEs in patients with CF. Treatment duration is currently based on the policies of each referral center and on individual response to treatment. Shorter treatment durations for APEs should improve the quality of life and satisfaction of patients and their families, as well as being less costly. However, this might not be sufficient to reduce the density of *P. aeruginosa* in the lungs significantly, potentially resulting in early recurrence of APE.

Although a systematic review concluded that there are insufficient data to recommend an appropriate treatment duration for an APE in patients with CF, most treatment regimens, in many centers worldwide, last 10–14 days (LE 4).

Two more recent studies have provided some interesting data on the subject. VanDevanter et al., in a retrospective study involving 95 hospitalized patients treated with two distinct antimicrobial regimens, found that the average time to the highest observed FEV₁ during the hospitalizations was 8.7 days (median = 10 days), and also reported that, in patients who had poor baseline pulmonary function (FEV₁ < 40%), the time to the highest observed FEV₁ was significantly longer (LE 3b). In another recent study (also retrospective), which evaluated more than 10,000 courses of intravenous antibiotic therapy in approximately 1,500 patients with CF, Collaco et al. showed that clinical and functional improvement was observed between day 7 and day 8 of therapy in most cases, indicating that shorter therapy durations can be used in some cases (LE 3b).

**Recommendation**

There is no clear definition in the literature as to what the duration of therapy for APEs
should be. However, the results suggest that antibiotics should be administered for at least 8-10 days, and patients who have worse baseline pulmonary function might require longer period of intravenous therapy (LE 3; GR C).

When should chronic inhaled antibiotic therapy be initiated in CF? Which inhaled antibiotics can be used in the treatment of chronic P. aeruginosa infection in CF?

Chronic P. aeruginosa infections have a negative impact on the prognosis of patients with CF, and, since the 1980s, there has been evidence that the use of therapies that decrease the amount of P. aeruginosa in the bronchial tree contributes to the stabilization or improvement of the disease.\(^{65,66}\)

Tobramycin is the most studied inhaled antibiotic, since a specific formulation of tobramycin (Tobi\(^{®}\); Novartis, São Paulo, Brazil) has been developed and tested in randomized, double-blind, placebo-controlled clinical trials involving a large number of patients with CF.\(^{2}\)

In the initial studies, inhaled tobramycin was compared with inhaled placebo or standard therapy in patients with moderate to severe lung disease (FEV\(_1\) < 70% of predicted), and the largest of them involved a sample of 520 patients (LE 1).\(^{67}\) The three most significant studies had a total number of 619 randomized patients. The results showed statistically significant improvement in FEV\(_1\) in those who received tobramycin, with a 7.8-12.0% increase in pulmonary function (FEV\(_1\); LE 1b).\(^{67-69}\)

In addition, those three studies evaluated the influence of the use of inhaled tobramycin on the frequency of APEs, reporting a reduction in the number of hospitalizations and in the number of hospitalization days for the group treated with inhaled tobramycin (NE 1b).\(^{67-69}\) The frequency of reported adverse events, especially those related to tinnitus, throat problems, and voice changes, was low in all studies.

These results led to inhaled tobramycin being recommended by international guidelines as the primary treatment option for such cases.\(^{3}\)

Two studies,\(^{18,70}\) involving a total number of 202 patients, evaluated the use of inhaled tobramycin in patients with CF and mild lung disease (FEV\(_1\) between 70% and 89% of predicted).

Gibson et al., in a sample of 21 patients under 6 years of age with CF and P. aeruginosa detected by BAL culture, reported that the use of inhaled tobramycin resulted in a reduction in the amount of P. aeruginosa in the airways (LE 2b).\(^{38}\) Another study, involving 181 patients (6-15 years of age) with mild lung disease, compared the use of inhaled tobramycin with the use of standard therapy for 56 weeks and found a significant reduction in the occurrence of exacerbations requiring hospitalization (11.0% vs. 25.6%). The study was stopped early because of the magnitude of the observed impact (LE 1b).\(^{70}\) There was no significant improvement in FEV\(_1\), but those treated with inhaled tobramycin showed a significant improvement (10%) in forced expiratory flow values—FEF\(_{50}\%\) (LE 1b).\(^{70}\)

The quality of evidence for the use of inhaled tobramycin in patients with mild lung disease remains limited by the number of studies and by sample sizes, and the largest of those studies\(^{20}\) was stopped early because of the magnitude of the impact observed for respiratory exacerbations.

Other inhaled antibiotics are used in CF patients with chronic P. aeruginosa infection, but the amount of scientific evidence remains relatively sparse.\(^{2}\)

Inhaled colomycin remains the initial drug of choice for nebulization in patients with CF and chronic respiratory infection with P. aeruginosa in the United Kingdom.\(^{71}\) A comparative study of inhaled tobramycin (300 mg twice daily) and nebulized colomycin (1,000,000 IU twice daily) involving 115 patients showed that both therapies reduced the bacterial content of sputum samples and increased FEV\(_1\) values by 6.7% and 0.37%, respectively (NE 2b).\(^{72}\) There have been few studies on the use of other drugs, such as gentamicin, amikacin, and ceftazidime.\(^{2}\)

New drugs for inhalation have recently been tested in order to expand the range of therapeutic options, with benefits in the areas of tolerability, bacterial resistance, and practicality of administration, impacting patient safety and quality of life.

Inhaled aztreonam, a single-ring beta-lactam antibiotic (a monobactam), is one of the recently introduced drugs.\(^{73}\) One of the initial studies was a randomized, double-blind, placebo-controlled trial involving 211 patients over 6 years of age with CF, FEV\(_1\), between 25% and 75% of predicted, and chronic P. aeruginosa infection, all of whom
were using inhaled tobramycin regularly. The patients received 75 mg inhaled aztreonam or placebo, two or three times daily for 28 days, and were then monitored for another 56 days. The reported positive effects included a 21-day increase in the mean time to next respiratory exacerbation, improvement in mean quality of life scores, a 6.3% increase in VEF₁ (p = 0.001), and a reduction in sputum P. aeruginosa density. Adverse events were comparable between the groups. There was no change in susceptibility to P. aeruginosa for aztreonam (LE 2b). More recently, a study has been published that reports data on the use of inhaled aztreonam for a longer period of time (18 months). The study included 274 patients (mean age, 26 years) who had participated in other studies with inhaled aztreonam. It was an open-label study involving two regimens (75 mg two or three times daily) in alternate months. In addition to high adherence to treatment, pulmonary function and quality-of-life data improved with each course of the drug, there being no significant increase in bacterial resistance rates. Patients treated with three times-daily nebulization showed more significant improvement in pulmonary function and respiratory symptoms (LE 2b).

A novel dry-powder formulation of tobramycin delivered via an innovative inhaler was compared, in a non-inferiority study, with the commercially available inhaled tobramycin preparation. The study included 517 patients over 6 years of age with CF, FEV₁ between 25% and 75% of predicted, and a history of chronic P. aeruginosa infection for the last 6 months. The dry-powder formulation of tobramycin and the inhaled tobramycin preparation had similar efficacy in terms of FEV₁ and microbiological effect, although the former resulted in higher rates of adverse effects, such as dysphonia, cough, and dysgeusia. However, the dry-powder formulation of tobramycin resulted in higher scores on quality-of-life questionnaires (LE 1b). A formulation of levofloxacin (MP-376, Aeroquin) was tested in 151 CF patients with chronic P. aeruginosa infection (LE 2b). Three different doses (120 mg/day, 240 mg once daily, and 240 mg twice daily) were tested against placebo for 28 days. Sputum P. aeruginosa density was reduced by MP-376 treatment at all three different doses, and there was a dose-dependent increase (of up to 8.7%) in FEV₁, as well as a significant reduction in the occurrence of APEs. The drug was generally well tolerated relative to placebo (LE 2b).

A systematic review of the literature, published in 2011, summarized the available evidence on the use of inhaled antibiotics in patients with CF. The review made several comparisons using meta-analysis techniques. The conclusion was that inhaled antibiotics improve pulmonary function and reduce the rates of exacerbation of P. aeruginosa infection, and that the best evidence supports the use of inhaled tobramycin (LE 1a).

**Recommendation**

It is recommended that inhaled tobramycin be used in patients over 6 years of age with CF, chronic P. aeruginosa infection, and moderate or severe lung disease (FEV₁ < 70%; LE 1; GR A). The use of inhaled tobramycin in patients over 6 years of age with CF, chronic P. aeruginosa infection, and mild lung disease (FEV₁ between 70% and 89%) is recommended to reduce respiratory exacerbations (LE 2; GR B). The evidence for the use of inhaled tobramycin in the younger population (those under 6 years of age) remains too poor to allow any evidence-based recommendation. There are still few data on the use of other antibiotics, such as colomycin, gentamicin, and aztreonam, and there is no evidence to recommend that they be widely used.

**Does adherence to clinical treatment affect the prognosis of patients with CF?**

The treatment of patients with CF is based on the prevention of structural lung injury, the management of the nutritional status, with supplementation with enzymes and nutrients, the prevention of exacerbations, and the identification and treatment of comorbidities, allowing a good quality of life. Among daily treatments, respiratory therapy plays a prominent role because of its complexity, since it usually requires the assistance of another individual and it is a procedure that has a significant impact on disease progression. Given the complexity of the disease and the various objectives involved, it is clear that complex and aggressive treatment...
regimens are frequently used, which is very time-consuming for patients and their families.\(^8\)

In this setting of complex treatments and no set deadline for their completion, adherence to the recommended treatment is a factor that greatly impacts the clinical outcomes and prognosis of such patients.\(^7\)

Nebulizations are the most complex part of the pharmacological treatment, because they are very time-consuming and are increasingly recommended in patients with mild disease.\(^2\)

In a recent study involving adult patients with CF, the mean reported time spent on treatment activities was 108 min/day, and nebulized therapies accounted for 41 min of that time.\(^8\) Even in asthma patients, who spend much less time on drug administration, estimates of adherence to inhaled therapies range from 30% to 50%.\(^2\)

One of the reasons for poor adherence to treatment is lack of understanding of physician recommendations by patients and their families, who often also understand the same physician recommendation differently.\(^8\)

There is evidence that the low rates of adherence to medication use in CF are associated with poorer disease control, school absenteeism, and an increase in APEs (LE 2b).\(^4\) In general, the onset of adolescence further worsens the scenario, because that is the time when the lung disease usually progresses and is precisely the time when adherence to treatment becomes poorer.\(^8\) There is evidence that adherence is inversely proportional to patient age, as well as being intimately related to a more optimistic view of the disease.\(^8\)

Given that a study evaluating factors associated with poor adherence in children with asthma and CF identified common factors between the two diseases (forgetting, oppositional behaviors toward parents, difficulties with time management for procedures, side effects, difficulties swallowing pills, and taste of some medications), but also described many aspects that are specific to each disease, it is recommended that a disease-specific approach be applied to issues of adherence to treatment (LE 2b).\(^8\)

A study involving adult CF patients and self-reported adherence that was conducted in Brazil showed high adherence rates, which were higher than that perceived by the medical staff involved in the treatment of those individuals.\(^8\) Using other tools to measure adherence, such as pharmacy records, Eakin et al.\(^8\) showed that poor adherence was associated with a higher risk of APE requiring the use of intravenous antibiotics (LE 4). Analyzing supplemental health care data on reimbursement for the purchase of inhaled tobramycin, Briesacher et al.\(^8\) assessed the impact of adherence to this therapy on the clinical outcomes of patients with CF. Categorizing adherence as “low” (< 2 cycles/year), “medium” (2–3 cycles/year), and “high” (≥ 4 cycles/year), those authors reported that high adherence was identified in only 7% of patients, and that low adherence was associated with an increased risk of hospitalization, with higher costs to the health care system (LE 3b). It is of note that the recommended treatment regimen is at least 6 cycles/year.

**Recommendation**

Adherence to treatment in CF is related to the great treatment load required and is poorer in adolescence. Nebulized therapies and respiratory therapy have the worst rates of adherence, and there is evidence that these therapies affect relevant clinical outcomes, such as the need for hospitalization (LE 3; GR C).

**Is azithromycin efficacious in slowing the progression of lung disease in CF patients colonized with *P. aeruginosa*?**

Macrolides are bacteriostatic drugs that act by inhibiting bacterial protein synthesis by binding to the 50S ribosomal unit.\(^9\) In the 1980s, Japanese researchers described their experience in using low doses of erythromycin in diffuse panbronchiolitis, a disease that is accompanied by bronchiectasis and pulmonary suppuration.\(^9\) That initial experience motivated further studies using different macrolides in the treatment of respiratory diseases, such as CF, asthma, and bronchiolitis obliterans.\(^9\)

Possible mechanisms of action of macrolides in CF include actions in the microorganism, such as reduced *P. aeruginosa* virulence, delayed bactericidal effects, reduced bacterial adherence to the respiratory epithelium, decreased bacterial motility, and impaired biofilm production.\(^9\) Among the immunomodulatory actions of macrolides in the host are alteration in the neutrophil production of elastase, inhibition of
alveolar macrophage production of inflammatory cytokines, and decreased mucus hypersecretion.\textsuperscript{91,93}

Azithromycin is the most commonly used macrolide in patients with CF, and the first encouraging clinical trial was published in 2002: a 15-month randomized double-blind, placebo-controlled crossover trial evaluating 41 patients with CF.\textsuperscript{94} The primary outcome measure was change in FEV\textsubscript{1}, and azithromycin was dosed by body weight: ≤ 40 kg (250 mg/day) and > 40 kg (500 mg/day). The authors found significant improvement in pulmonary function (5.4%; 95% CI: 0.8–10.5%) in the group receiving azithromycin as compared with the group receiving placebo, and there was no significant difference in sputum bacterial concentration, exercise tolerance, or quality of life. In addition, treatment was well tolerated, with no significant adverse events (LE 2b).\textsuperscript{94}

Subsequently, a new, multicenter, randomized, double-blind, placebo-controlled trial involving 185 patients over 6 years of age who were chronically infected with \textit{P. aeruginosa} was conducted in the USA.\textsuperscript{95} The dose of azithromycin was the same as that of the previous study, although it was administered only three times weekly. The primary outcome measure was also FEV\textsubscript{1}, and the authors reported a significant difference between the treatment and placebo groups (6.2%; 95% CI: 2.6–9.8%). Other encouraging results were a 35% reduction in the risk of APE and significant weight gain among the patients receiving azithromycin (LE 1b).\textsuperscript{96} The same group of authors assessed the effects of azithromycin in CF patients uninfected with \textit{P. aeruginosa};\textsuperscript{96} the use of azithromycin for 24 weeks did not result in significant improvement in FEV\textsubscript{1} when compared with that of placebo, but there was a significant reduction in the occurrence of APEs in the group treated with azithromycin (LE 2b).\textsuperscript{96}

A recent meta-analysis evaluating the use of macrolides in patients with CF included 6 randomized placebo-controlled trials (654 patients).\textsuperscript{97} Treatment with azithromycin resulted in significant improvement in FEV\textsubscript{1} and FVC, especially in patients chronically infected with \textit{P. aeruginosa}. The incidence of side effects was not significantly different between the placebo group and the azithromycin group (LE 1a).\textsuperscript{97}

A recent systematic review on the use of macrolides in CF included 10 studies (959 patients).\textsuperscript{98} Four clinical trials (549 patients) reported significant improvement in pulmonary function by comparing azithromycin with placebo. The mean difference at 6 months was 3.97% (95% CI: 1.74–6.19%). Patients receiving azithromycin had a reduction in the occurrence of APEs, needed oral antibiotics less frequently, had greater weight gain, and had fewer respiratory secretion cultures positive for \textit{S. aureus}. Adverse effects were uncommon, although there was an increase in resistance to macrolides. The authors concluded that azithromycin has a small beneficial effect in the treatment of patients with CF using a three-times-weekly regimen for periods of 6 months. However, considering the limited long-term data available and the concern about the development of bacterial resistance to macrolides, the current evidence is not strong enough to recommend that azithromycin be used in all patients with CF (LE 1a).\textsuperscript{98}

**Recommendation**

The use of azithromycin in CF patients chronically infected with \textit{P. aeruginosa} causes slight improvement in pulmonary function, reduces the frequency of APEs, and has no significant side effects (LE 1; GR A).

Because most studies lasted approximately 6 months, long-term studies are needed to confirm the efficacy and safety of azithromycin.

**Is there a good correlation between antibiogram results and clinical response in chronic \textit{P. aeruginosa} infection?**

In initial infection with \textit{P. aeruginosa} in patients with CF, nonmucoid forms are usually quite sensitive, there is a good correlation with antibiogram results, and treatment is usually successful. In chronic infections, mucoid forms of \textit{P. aeruginosa} predominate, and higher concentrations of antibiotics are required; in addition, given the common occurrence of mixed populations of \textit{P. aeruginosa} in the biofilm in the lung, the correlation between antibiogram results and clinical response might not be good.\textsuperscript{71}

There are reports of clinical success in the treatment of bacteria that are resistant in vitro, and, in a study involving treatment of APEs, clinical outcomes were not associated with the minimum inhibitory concentration values
for \textit{P. aeruginosa} of the antimicrobial agents used (LE 2b).\textsuperscript{99}

In a study addressing multidrug-resistant \textit{P. aeruginosa} isolates, Aaron et al.\textsuperscript{100} found no significant differences in clinical or bacteriological outcomes between the antimicrobial regimen chosen on the basis of standard sensitivity testing and that chosen on the basis of multiple combination bactericidal antibiotic testing (synergy testing; LE 2b).

Despite the lack of correlation found between antibiogram results and clinical response in the treatment of \textit{P. aeruginosa} infections, the recommendation is to perform cultures of respiratory secretions from CF patients periodically to detect the initial infection, as well as to monitor changes in sensitivity patterns or the presence of other pathogens, such as \textit{B. cepacia} complex, \textit{Achromobacter xylosoxidans}, \textit{Aspergillus} spp., etc. (LE 5; GR D).

\textbf{Recommendation}

Despite the poor correlation between antibiogram results and clinical response in chronic \textit{P. aeruginosa} infection, it is recommended that cultures of respiratory secretions from CF patients be performed periodically to identify different bacterial species, although \textit{P. aeruginosa} treatment should not be directed solely by the sensitivity pattern in the antibiogram (LE 5; GR D).

\textbf{Does multidrug-resistant \textit{P. aeruginosa} infection worsen prognosis?}

As the mean survival of patients with CF increases and the population of adults with CF grows, there is increasing concern about multidrug-resistant \textit{P. aeruginosa} infections. Multidrug-resistant \textit{P. aeruginosa} has been defined as resistance to all drugs in at least two of the three following antimicrobial classes: fluoroquinolones; beta-lactam antibiotics; and aminoglycosides.\textsuperscript{102}

The major risk factors for multidrug-resistant \textit{P. aeruginosa} infection are diabetes, long-term use of inhaled tobramycin, and frequent APEs requiring hospitalization or intravenous antibiotics. Receiving care at a treatment center with a high prevalence of resistant \textit{Pseudomonas} spp. also increases the risk for acquiring multidrug-resistant \textit{P. aeruginosa} (LE 2b).\textsuperscript{103}

A study following 75 adult patients with CF over a 3-year period found that multidrug-resistant \textit{P. aeruginosa} infection was associated with greater lung disease severity, more rapid decline in FEV\(_1\), increased use of intravenous antibiotics, and increased frequency of medical visits (LE 2b).\textsuperscript{104}

\textbf{Final considerations}

There is a body of evidence that early \textit{P. aeruginosa} colonization has a significant impact on the prognosis of patients with CF, and that eradication strategies should be used, although there is controversy as to what is the best treatment regimen for this purpose. Early diagnosis of \textit{P. aeruginosa} infection remains a challenge in clinical practice, and the role of \textit{P. aeruginosa} serology in routine practice has yet to be established. A major problem for patients with CF, APEs are difficult to identify and treat, which often results in significant functional loss. Maintenance treatment for patients with chronic \textit{P. aeruginosa} infection includes drugs such as azithromycin and inhaled antibiotics and, despite the body of evidence supporting the use of inhaled tobramycin, there is a novel formulation of this drug, as well as other antimicrobial agents with potential for use in such cases.

\textbf{References}

1. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361(9358):681-9. http://dx.doi.org/10.1016/S0140-6736(03)12567-6
2. Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-69. http://dx.doi.org/10.1164/rccm.200705-664OC PMId:17761616
3. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care. 2009;54(5):595-605. http://dx.doi.org/10.4187/aarc0427 PMId:19393104
4. Lommatzsch ST, Aris R. Genetics of cystic fibrosis. Semin Respir Crit Care Med. 2009;30(5):531-8. http://dx.doi.org/10.1055/s-0029-1238911 PMId:19760540
5. Ratjen F. Diagnosing and managing infection in CF. Paediatr Respir Rev. 2006;7 Suppl 1:S151-3. http://dx.doi.org/10.1016/j.prrv.2006.04.217 PMId:16798546

J Bras Pneumol. 2013;39(4):495-512
6. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996;60(3):539-74. PMID:8840786

7. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581-8. http://dx.doi.org/10.1001/jama.293.5.581 PMID:15687313

8. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-51. http://dx.doi.org/10.1164/rccm.200304-505SO PMID:14555458

9. Deschaght P, Van Daele S, De Baets F, Vanchezoutte M. PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature review. J Cyst Fibros. 2011;10(5):293-7. http://dx.doi.org/10.1016/j.jcf.2011.05.004 PMID:21684819

10. Nixon GM, Armstrong D, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138(5):569-74. http://dx.doi.org/10.1067/mjp.2001.112897 PMID:11343046

11. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12(3):158-61. http://dx.doi.org/10.1002/ppul.1950120306 PMID:16141272

12. Tacetti G, Campagna S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26(3):458-61. http://dx.doi.org/10.1183/09031936.05.0009605 PMID:16135728

13. CEBM Centre For Evidence Based Medicine [homepage on the Internet]. Oxford: University of Oxford. [cited 2013 Feb 11]. “The Oxford 2011 Levels of Evidence. Available from: http://www.cebm.net/index.aspx?o=5653

14. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34. http://dx.doi.org/10.1016/S1389-2977(03)00141-8

15. Corey M. Survival estimates in cystic fibrosis: snapshots of a moving target. Pediatr Pulmonol. 1996;21(3):149-50. http://dx.doi.org/10.1002/1099-0496(199603321:3<149::AID-PULM1950210302>3.0.CO;2-C

16. Hudson VL, Wielincki CI, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr. 1993;122(6):854-60. http://dx.doi.org/10.1016/S0022-3476(06)9000075

17. Kosorok MR, Zeng L, West SE, Rock MJ, Slaipraingad ML, Laxowa A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32(4):277-87. http://dx.doi.org/10.1002/ppul.100127 PMID:12112774

18. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100. http://dx.doi.org/10.1002/ppul.10127 PMID:12112774

19. Lebecque P, Leal T, Ziyberberg K, Reychler G, Bossuyt X, Godding V. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2006;5(4):237-44. http://dx.doi.org/10.1016/j.jcf.2006.04.001 PMID:16790367

20. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med. 2006;12(6):428-32. http://dx.doi.org/10.1097/01.mcp.0000245712.51514.a1 PMID:17053493

21. Equi AC, Pike SE, Davies J, Bush A. Use of cough swabs in a cystic fibrosis clinic. Arch Dis Child. 2001;85(5):438-9. http://dx.doi.org/10.1136/adc.85.5.438 PMID:11668115

22. da Silva Filho LV, Tateno AF, Martins MM, Azzuz Chemishev AC, Garcia Dde O, Haug M, et al. The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis. Pediatr Pulmonol. 2007;42(10):938-44. http://dx.doi.org/10.1002/ppul.20686 PMID:17722007

23. Holby N, Flensburg EW, Beck B, Frlis B, Jacobsen SV, Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977;58(2):65-79. PMID:404701

24. Brett MM, Ghoneim AT, Littlewood JM. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol. 1988;26(8):1565-70. Erratum in: J Clin Microbiol 1989;27(1):230. PMID:319707 PMID:266661

25. West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002;287(22):2958-67. http://dx.doi.org/10.1001/jama.2002.287.22.2958 PMID:12052125

26. Kappler M, Kraxner A, Reinhardt D, Ganster B, Greise M, Lang T. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax. 2006;61(8):684-8. http://dx.doi.org/10.1136/thx.2005.049536 PMID:16492595

27. Tramper-Stranders GA, van der Ent CK, Slieter MG, Terheggen-Lagro SW, Teding van Berkhout F, Kimpen JL, et al. Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax. 2006;61(8):689-93. http://dx.doi.org/10.1136/thx.2005.054726 PMID:16601093

28. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol. 2007;42(3):249-55. http://dx.doi.org/10.1002/ppul.20562 PMID:17243185

29. Weisner AM, Chart H, Bush A, Davies JC, Pitt TL. Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis. J Med Microbiol. 2007;56(Pt 5):670-4. http://dx.doi.org/10.1099/jmm.0.46833-0 PMID:17446292

30. Pressler T, Karpati F, Granström M, Knudsen PK, Lindblad A, Hjelte L, et al. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros. 2008;7(1):37-42. http://dx.doi.org/10.1016/j.jcf.2007.08.002 PMID:18835753

31. Milagres LG, Castro TL, Garcia D, Cruz AC, Higa L, Folescu T, et al. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pulmonol. 2009;44(4):392-401. http://dx.doi.org/10.1002/ppul.21022 PMID:19283764
Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment

32. Hayes D Jr, Farrell PM, Li Z, West SE. Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening. Pediatr Pulmonol. 2010;45(1):55-61. http://dx.doi.org/10.1002/ppul.21083 PMid:20025049 PMCID:2924665

33. Douglas TA, Brennan S, Berry L, Winfield K, Wainwright CE, Grimwood K, et al. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax. 2010;65(1):985-90. http://dx.doi.org/10.1136/thx.2009.132845 PMid:20889526

34. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA. 2011;306(2):163-71. http://dx.doi.org/10.1001/jama.2011.954 PMid:21750293

35. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet. 1985;1(8433):865. http://dx.doi.org/10.1016/0140-6736(85)92222-6

36. Valerius NH, Koch C, Holby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725-6. http://dx.doi.org/10.1016/0140-6736(91)91446-2

37. Muncu A, Bonacorsi S, Mariani-Kurkdjian P, Le Bourgeois M, Gérardin M, Brahimi N, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol. 2001;32(4):288-92. http://dx.doi.org/10.1002/ppul.1121 PMid:11568989

38. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):841-9. http://dx.doi.org/10.1164/rccm.200208-855OC PMid:12480612

39. Davidson AG, Chilver MA, Lillquist YP. Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic. Curr Opin Pulm Med. 2012;18(6):442-7. http://dx.doi.org/10.1016/j.copul.2012.04.005 PMid:22990661

40. Tré-Hardy M, Nagant C, El Manssouri N, Vanderbist CE, Grimwood K, et al. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Clin Microbiol Infect. 2011;17(8):E390-7. http://dx.doi.org/10.1111/j.1469-0691.2011.03806.x PMid:21810839

41. Rijnders E, Vanpoucke K, Van Parijs M, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. J Cyst Fibros. 2011;10 Suppl 2:S79-81. http://dx.doi.org/10.1016/S1168-1025(11)70019-X

42. Balagué A, González de Dios J. Home versus hospital intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev. 2012;2:CD009197. PMid:22419283

43. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3. Management. Thorax. 2008;63(3):180-4. http://dx.doi.org/10.1136/thx.2006.060905 PMid:18234661

44. Smyth A, Knox A. Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J Cyst Fibros. 2011;10(5):383. http://dx.doi.org/10.1016/j.jcf.2011.03.010 PMid:21507733

45. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8):419-26. http://dx.doi.org/10.1016/j.tim.2011.04.005 PMid:21664819

46. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley D, C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348(9028):639-42. http://dx.doi.org/10.1016/S0140-6736(96)05169-0

47. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2005;(2):CD002007. PMid:15846627

48. Bosco JA, Saxon BA, Matsen JM. Comparative activity of ceftizoxime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. Antimicrob Agents Chemother. 1991;35(4):783-4. http://dx.doi.org/10.1128/AAC.35.4.783 PMid:1906264 PMCID:245101

49. Tré-Hardy M, Nagan C, El Manoussri N, Vanderbist F, Traore V, Vaneechoutte M, et al. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother. 2010;54(10):4409-15. http://dx.doi.org/10.1128/AAC.00372-10 PMid:20696878 PMCID:2944582

50. Leroy A, Humbert G, Oksenhendler G, Fillastre JP. Pharmacokinetics of aminoglycosides in subjects with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-42. http://dx.doi.org/10.1056/NEJM19940908311003 PMid:7503821

51. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001;139(3):359-65. http://dx.doi.org/10.1067/mjp.2001.117288 PMid:11562614

52. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol. 2001;31(6):436-42. http://dx.doi.org/10.1002/ppul.1072 PMid:11389576

53. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-8. http://dx.doi.org/10.1164/rccm.200812-1845PP PMid:19729669

54. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011;17(6):442-7. PMid:21881509

55. Bilton D, Canny G, Conway S, Dumuscus S, Hjelte L, Proesmans M, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10 Suppl 2:S79-81. http://dx.doi.org/10.1016/S1168-1025(11)70019-X

56. Carlin JB, Cheney J, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA. 2011;306(2):163-71. http://dx.doi.org/10.1001/jama.2011.954 PMid:21750293

57. Lungerson J, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-42. http://dx.doi.org/10.1056/NEJM19940908311003 PMid:7503821
normal and impaired renal function. Antibiot Chemother. 1978;25:163-80. PMid:352252

59. Kovarik JM, Hoepelman IM, Verhoef J. Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis. 1989;8(9):761-9. http://dx.doi.org/10.1007/BF02185842 PMid:2512146

60. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39(6):677-86. http://dx.doi.org/10.1093/jac/39.6.677 PMid:922035

61. Contopoulos-Ioannidis DG, Giotis ND, Ballatis DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004;114(1):e111-8. http://dx.doi.org/10.1542/peds.114.1.e111 PMid:1523982

62. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2012;2:CD002009. PMid:22336782

63. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2011;1:CD006682. PMid:21249681

64. VanDevanter DR, O’Riordan MA, Blumer JL, Konstan MW. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res. 2010;11:137. http://dx.doi.org/10.1186/1465-9921-11-137 PMid:20925941 PMid:2959026

65. Hudson ME, Penketh AR, Batten JC. Aerosol carbencillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981;2(8256):1137-9. http://dx.doi.org/10.1016/S0140-6736(81)90588-2

66. Saaf M, Holby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983;72(5):651-7. http://dx.doi.org/10.1111/j.1651-2227.1983.tb09789.x PMid:6637463

67. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. J Med. 1999;340(1):23-30. http://dx.doi.org/10.1056/NEJM199901073400104 PMid:9878641

68. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cyst Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30. http://dx.doi.org/10.1056/NEJM199901073400104 PMid:9878641

69. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42-8. http://dx.doi.org/10.1002/ppul.1950070110 PMid:2505216

70. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38(4):314-20. http://dx.doi.org/10.1002/ppul.20097 PMid:15334509

71. Cystic Fibrosis Trust [homepage on the Internet]. Bromley: Cystic Fibrosis Trust. [cited 2013 Feb 11]. Antibiotic treatment for cystic fibrosis 2009. [Adobe Acrobat document, 102p.]. Available from: https://www.cysticfibrosis.org.uk/media/82010/CD_Antibiotic_treatment_for_CF_May_09.pdf

72. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658-64. http://dx.doi.org/10.1183/09031936.02.00248102 PMid:12358344

73. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-8. http://dx.doi.org/10.1164/rccm.200712-1804OC PMid:18658109 PMid:2575777

74. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45(11):1121-34. http://dx.doi.org/10.1002/ppul.21301 PMid:20672296

75. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011;10(1):34-61. http://dx.doi.org/10.1016/j.jcf.2010.10.003 PMid:21075062

76. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183(11):1510-6. http://dx.doi.org/10.1164/rccm.201008-1293OC PMid:21471106

77. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2011;3:CD001021. PMid:21412868

78. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012;47(6):523-33. http://dx.doi.org/10.1002/ppul.22546 PMid:22467341

79. Robinson P. Cystic fibrosis. Thorax. 2001;56(3):237-41. http://dx.doi.org/10.1136/thorax.56.3.237 PMid:11182019 PMCid:1758774

80. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2 . prevention. Thorax. 2007;62(8):723-32. http://dx.doi.org/10.1136/thx.2006.060897 PMid:17687099 PMCid:2117269

81. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91-6. http://dx.doi.org/10.1016/j.jcf.2008.09.007 PMid:18952504 PMCid:2680350

82. Millgram H, Bender B, Ackerman L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol. 1996;98(6 Pt 1):1051-7. http://dx.doi.org/10.1016/S0091-6749(96)80190-4

83. Lewis CE, Brown RT, Drotar D, Caplan D, Pshevar BS, Lambert RG. Knowledge of physician prescriptions and adherence to treatment among children with cystic fibrosis and their mothers. J Dev Behav Pediatr. 1999;20(5):335-43. http://dx.doi.org/10.1097/00004703-199910000-00008 PMid:10533992

84. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care. 2005;50(10):1346-56; discussion 1357-9. PMid:16185370

85. DiGirolamo AM, Quittner AL, Ackerman V, Stevens J. Identification and assessment of ongoing stressors in adolescents with a chronic illness: an application of the behavior-analytic model. J Clin Child Psychol. 1997;26(1):53-66. http://dx.doi.org/10.1207/s15374424jccp2601_6 PMid:9118176
Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment

86. Gudas LJ, Koocher GP, Wypij D. Perceptions of medical compliance in children and adolescents with cystic fibrosis. J Dev Behav Pediatr. 1991;12(4):236-42. http://dx.doi.org/10.1097/00004703-199108000-00004 PMid:1939678

87. Modi AC, Quittert AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol. 2006;31(8):846-58. http://dx.doi.org/10.1093/jpepsy/jsp096 PMid:16401680

88. Dalicin Pde T, Rampon G, Pasin LR, Ramon GM, Abrahão CL, Oliveira VZ. Adherence to treatment in patients with cystic fibrosis. J Bras Pneumol. 2007;33(6):663-70. PMid:18200366

89. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Rieker K. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258-64. http://dx.doi.org/10.1016/j.jcf.2011.03.005 PMid:21458391 PMcid:3114200

90. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quitrell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5. http://dx.doi.org/10.1186/1471-2466-11-5 PMid:21251275 PMcid:3033861

91. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Paediatr Respir Rev. 2005;6(3):227-35. http://dx.doi.org/10.1016/j.prrv.2005.06.005 PMid:1613572

92. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [Article in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi. 1987;25(6):632-42. PMid:3682440

93. McAndie JR, Talwalkar JS. Macrolides in cystic fibrosis. Clin Chest Med. 2007;28(2):347-60. http://dx.doi.org/10.1016/j.ccm.2007.02.005 PMid:17467553

94. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360(9338):978-84. http://dx.doi.org/10.1016/S0140-6736(02)11081-6

95. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittert AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-56. http://dx.doi.org/10.1001/jama.290.13.1749 PMid:14519709

96. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Tmkac J, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707-15. http://dx.doi.org/10.1001/jama.2010.563 PMid:20442386

97. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother. 2011;66(5):968-78. http://dx.doi.org/10.1093/jac/dkr040 PMid:21393178

98. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2011;(12):CD002203. PMid:22161368

99. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003;123(5):1495-502. http://dx.doi.org/10.1378/chest.123.5,1495 PMid:12740266

100. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005;366(9484):463-71. http://dx.doi.org/10.1016/S0140-6736(05)67060-2

101. Cantón R, Cobos N, de Gracia J, Baquerro F, Honoroato J, Gartner S, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11(9):690-703. http://dx.doi.org/10.1111/j.1469-0691.2005.01217.x PMid:16104983

102.Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis. 1996;23(3):532-7. http://dx.doi.org/10.1093/clinids/23.3.532 PMid:8879776

103.Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007;132(2):562-8. http://dx.doi.org/10.1378/chest.06-2888 PMid:17646236

104. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006;73(1):27-33. http://dx.doi.org/10.1159/000087686 PMid:16113513

J Bras Pneumol. 2013;39(4):495-512
About the authors

Luiz Vicente Ribeiro Ferreira da Silva Filho
Médico Assistente Doutor. Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.

Flavia de Aguiar Ferreira
Gerente Médica. Novartis Brasil, São Paulo (SP) Brasil.

Francisco José Caldeira Reis
Presidente. Grupo Brasileiro de Estudos em Fibrose Cística, Belo Horizonte (MG) Brasil.

Murilo Carlos Amorim de Britto
Médico. Instituto Materno Infantil de Pernambuco, Recife (PE) Brasil.

Carlos Emilio Levy
Diretor. Divisão de Patologia Clínica, Hospital das Clínicas, Universidade Estadual de Campinas, Campinas (SP) Brasil.

Otavio Clark
Diretor. Evidências Consultoria, Campinas (SP) Brasil.

José Dirceu Ribeiro
Professor Titular de Pediatria. Universidade Estadual de Campinas, Campinas (SP) Brasil.